US FDA approves Sanofi’s Xenpozyme as first disease-specific treatment for non-CNS manifestations

Press/Media

Period	2 Sep 2022

Media coverage

Title	US FDA approves Sanofi’s Xenpozyme as first disease-specific treatment for non-CNS manifestations
Media name/outlet	PharmaBiz
Country/Territory	India
Date	2/09/22
URL	www.pharmabiz.com/NewsDetails.aspx?aid=152965&sid=2
Persons	Melissa Wasserstein